AHZ.AX - Anteris Technologies Ltd

ASX - ASX Delayed price. Currency in AUD
7.20
-0.20 (-2.70%)
At close: 4:10PM AEST
Stock chart is not supported by your current browser
Previous close7.40
Open7.40
Bid7.20 x 0
Ask7.30 x 0
Day's range7.20 - 7.50
52-week range0.06 - 9.18
Volume5,713
Avg. volume4,783
Market cap42.554M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Admedus Changes Name to Anteris Technologies Ltd

    Admedus Limited (ASX:AHZ), announced today that it has changed the Company’s name to Anteris Technologies Ltd (“Anteris”). As of May 22, 2020 Anteris, is trading on the Australian Securities Exchange under the ticker AVR. This milestone signifies the completion of Admedus’ restructuring program focused on transitioning to a dedicated structural heart company anchored by ADAPT®, a next generation regenerative bioscaffold platform technology being utilized to address multiple cardiovascular procedures and repairs including, a product (DurAVR™) in development for Transfemoral Aortic Valve Replacement (TAVR) procedures.

  • Why Admedus Limited's (ASX:AHZ) CEO Pay Matters To You
    Simply Wall St.

    Why Admedus Limited's (ASX:AHZ) CEO Pay Matters To You

    Wayne Paterson has been the CEO of Admedus Limited (ASX:AHZ) since 2016. First, this article will compare CEO...

  • Can You Imagine How Chuffed Admedus's (ASX:AHZ) Shareholders Feel About Its 102% Share Price Gain?
    Simply Wall St.

    Can You Imagine How Chuffed Admedus's (ASX:AHZ) Shareholders Feel About Its 102% Share Price Gain?

    When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...

  • Is Admedus Limited (ASX:AHZ) Overpaying Its CEO?
    Simply Wall St.

    Is Admedus Limited (ASX:AHZ) Overpaying Its CEO?

    Wayne Paterson became the CEO of Admedus Limited (ASX:AHZ) in 2017. First, this article will compare CEO compensation...

  • GlobeNewswire

    LeMaitre Vascular Acquires Biologic Patch Business from Admedus

    The acquired patches, marketed under the brands CardioCel® and VascuCel®, are processed in a manner that is intended to reduce the risk of calcification.  Annualized 2019 sales of these product lines were $7.1 million, mostly in the US and Europe. Guidance on how this acquisition may affect LeMaitre Vascular’s 2019 revenue, operating income and EPS expectations will be provided at the Company’s Q3 2019 earnings call on October 23, 2019.